Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative bioavailability study of pediatric TMC207 formulations in healthy adults
NL-OMON38686Phase 1Active, not recruiting
- Sponsor
- Johnson & Johnson
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bedaquiline in Tuberculosis (TB) (3 arms), sponsored by Johnson & Johnson. Primary endpoint: Relative bioavailability of TMC207. Started Apr 2013; status: active, not recruiting.
02
Drugs
bedaquiline
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NL-OMON38686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38686.